pyrazines has been researched along with ATLL in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (75.00) | 29.6817 |
2010's | 3 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ambinder, RF; Forde, PM; Gladstone, DE; Hourigan, CS | 1 |
Bamford, RN; Conlon, KC; Ju, W; Maeda, M; Nakagawa, M; Petrus, MN; Waldmann, TA; Yu, P; Zhang, M | 1 |
Ishitsuka, K; Katsuya, H; Kunami, N; Nogami, R; Tamura, K | 1 |
Ding, J; Iida, S; Inagaki, A; Ishida, T; Ito, A; Komatsu, H; Kusumoto, S; Ri, M; Ueda, R; Utsunomiya, A; Yano, H | 1 |
Brady, JN; Dohoney, K; Janik, JE; Lee, MJ; Morris, JC; O'Mahony, D; Pise-Masison, CA; Radonovich, M; Trepel, J; Waldmann, TA | 1 |
Chen, Z; Gong, S; Lü, S; Wang, J; Xu, X; Yang, J; Zhou, H | 1 |
Koya, Y; Matsuoka, M; Nosaka, K; Satou, Y; Toyokuni, S; Yasunaga, JI | 1 |
Hatake, K; Mishima, Y; Terui, Y | 1 |
Matsuoka, M; Satou, Y | 1 |
Arnulf, B; Bazarbachi, A; Bex, F; Dbaibo, G; de Thé, H; El-Sabban, ME; Hermine, O; Karam, JA; Kfoury, Y; Lepelletier, Y; Nasr, R | 1 |
Utsunomya, A | 1 |
Tan, C; Waldmann, TA | 1 |
3 review(s) available for pyrazines and ATLL
Article | Year |
---|---|
[Proteasome inhibitors].
Topics: Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cysteine Endopeptidases; Humans; Kidney Neoplasms; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multienzyme Complexes; Multiple Myeloma; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
[Proteasome inhibitor, bortezomib (Vercade), potently inhibits the growth of adult T-cell leukemia cells].
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Humans; Leukemia-Lymphoma, Adult T-Cell; Multienzyme Complexes; Proteasome Endopeptidase Complex; Pyrazines | 2004 |
[Clinical and hematological characteristics of adult T-cell leukemia/lymphoma].
Topics: Benzamides; Boronic Acids; Bortezomib; Carrier State; Cyclohexanones; HIV Protease Inhibitors; Human T-lymphotropic virus 1; Humans; Infectious Disease Transmission, Vertical; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Protease Inhibitors; Pyrazines; Ritonavir; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
9 other study(ies) available for pyrazines and ATLL
Article | Year |
---|---|
Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Pyrazines; Salvage Therapy; Treatment Outcome | 2013 |
Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Benzodiazepinones; beta 2-Microglobulin; Biomarkers, Tumor; Boronic Acids; Bortezomib; Depsipeptides; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation, Leukemic; Humans; Interleukin-2 Receptor alpha Subunit; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Pyrazines; Receptor, Notch1; Signal Transduction; Tumor Burden | 2015 |
Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia-Lymphoma, Adult T-Cell; Nitrophenols; Piperazines; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; Vorinostat | 2014 |
Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Humans; Immunoprecipitation; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell, Cutaneous; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2009 |
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Boronic Acids; Bortezomib; CD4-Positive T-Lymphocytes; Cell Survival; Daclizumab; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Inhibitor of Apoptosis Proteins; Leukemia-Lymphoma, Adult T-Cell; Male; Microtubule-Associated Proteins; Middle Aged; Pyrazines; RNA Interference; Survivin; Transcription Factor 4; Transcription Factors; Tumor Cells, Cultured | 2009 |
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Topics: Antineoplastic Agents; Base Sequence; Boronic Acids; Bortezomib; DNA Primers; Drug Resistance, Neoplasm; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Mutation; Proteasome Endopeptidase Complex; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line, Transformed; Cell Line, Tumor; Cysteine Endopeptidases; HTLV-I Infections; Humans; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, SCID; Multienzyme Complexes; Neoplasm Transplantation; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Transplantation, Heterologous | 2004 |
Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma.
Topics: Adult; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Division; Cell Line; Cell Line, Tumor; Cell Survival; Ceramides; Humans; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Protease Inhibitors; Proteasome Inhibitors; Pyrazines | 2005 |
Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Daclizumab; DNA-Binding Proteins; DNA, Neoplasm; Drug Synergism; Humans; I-kappa B Proteins; Immunoglobulin G; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Monocytes; Multienzyme Complexes; Neutrophils; NF-kappa B; NF-KappaB Inhibitor alpha; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Receptors, IgG | 2002 |